The Journal of infectious diseases · 2026
Hydrogen Cyanide Generation by Pseudomonas aeruginosa Blunts the Host Innate Immune Response.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Szabo Csaba, Santos Sidnéia Sousa, Findlay Jacqueline, Bremer Olivier, Petrosino Maria, Philipp Thilo Magnus, Kierońska-Rudek Anna, Zuhra Karim, Boss Gerry R, Nordmann Patrice
Аннотация
BACKGROUND: The biological mediator hydrogen cyanide (HCN) is produced by certain pathogenic bacteria. Hydrogen cyanide exerts multiple effects in mammalian cells: at low concentrations, it has cytoprotective regulatory effects, whereas at high concentrations, it blocks mitochondrial electron transport by inhibiting cytochrome c oxidase, thereby halting cellular metabolism. Here, we evaluated whether bacterial HCN confers resistance to the host immune response. We used Pseudomonas aeruginosa as a model organism, since it is a clinically significant HCN-generating bacterial species and a common cause of nosocomial infections.
METHODS: The study used bacterial mutants, macrophage co-cultures, cyanide quantification, phagocytosis and bioenergetics assays, and mouse infection models to assess HCN's role in immune evasion.
RESULTS: Compared with wild-type P. aeruginosa, genetically HCN-deficient bacteria were more susceptible to killing by immune cells in vitro and were cleared more rapidly in mouse models of systemic infection. Increased leukocyte killing was not due to increased phagocytosis. Pharmacological scavenging of HCN also enhanced leukocyte bacterial killing.
CONCLUSIONS: These findings support the concept that HCN acts as a bacterial defense mechanism against the host's immune response. Targeting bacterial HCN could be a potential therapeutic strategy to improve the immune clearance of P. aeruginosa infections.
METHODS: The study used bacterial mutants, macrophage co-cultures, cyanide quantification, phagocytosis and bioenergetics assays, and mouse infection models to assess HCN's role in immune evasion.
RESULTS: Compared with wild-type P. aeruginosa, genetically HCN-deficient bacteria were more susceptible to killing by immune cells in vitro and were cleared more rapidly in mouse models of systemic infection. Increased leukocyte killing was not due to increased phagocytosis. Pharmacological scavenging of HCN also enhanced leukocyte bacterial killing.
CONCLUSIONS: These findings support the concept that HCN acts as a bacterial defense mechanism against the host's immune response. Targeting bacterial HCN could be a potential therapeutic strategy to improve the immune clearance of P. aeruginosa infections.